大行評級 | 高盛:重申匯豐控股(0005.HK)買入評級 目標價升至70港元
格隆匯6月29日丨高盛發表報告表示,匯豐控股(0005.HK)將於8月1日公佈今年第二季業績,料集團第二季除稅前盈利39.28億美元按年跌22%(按季跌6%)、估計次季純利25.67億美元按年跌24%(按季跌8%)。
該行預料美國息率趨升下,會爲匯控(0005.HK)帶來穩健的利潤率擴張,在今年下半年港元利率走向或有利於集團利潤表現,並預料其銀行淨利息收入於明年年中加速及達致頂峯(升20%以上)。該行重申對匯控“買入”投資評級,上調對其未來12個月目標價由65港元升至70港元,並調高對匯控2022年至2025年每股盈利預測各1%、11%、9%及5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.